Company intelligence / Profile preview

Canthevac

Ownership: Private
Development stage: Preclinical

Overview

Canthevac is developing innovative vaccines and cancer therapeutics using advanced technologies. However, specific clinical results are not detailed in the available information.

Therapeutic areas: Oncology
Modalities: VaccinesImmunotherapyAI-driven protein designLive-attenuated viral vectorsLipid nanoparticlesmRNA encoding AI-based structure-guided neoantigens
Industry: Biotech

Drug pipeline

9 assets

IBIS-Influenza

Preclinical

8 more assets in the full pipeline.

Request access →

Partnerships

Centre for Virology, Vaccinology, and Therapeutics (CVVT)The University of Hong Kong

Beyond the preview

Go deeper on Canthevac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canthevac.

Explore the full profile